Clinical Characteristics of Social Cognitive Processes in Major Depressive Disorder

Author(s):  
Katharina Foerster ◽  
Silke Joergens ◽  
Bernhard T. Baune

Dysfunctional social cognition describes an important symptom of major depressive disorder (MDD). This dysfunction relates to various aspects of perception of emotional states in oneself and in others, but also applies to complex situations such as social communication. The majority of evidence supports a theory that patients with MDD show a negative bias towards ambiguous emotional information in all domains of social perception. It appears that social cognitive function varies in the course of MDD due to treatment and symptom severity. Therefore, social cognitive dysfunction often presents as a subtle phenomenon vulnerable to further disturbing influences by confounding variables. Analyses often do not consider important confounders such as symptom severity and type of treatment. Social cognitive research uses a broad spectrum of measurements with varying quality of standard psychometric criteria. Future investigations should use standardized measures with large normative samples to avoid distortions of results.

2013 ◽  
Vol 5 (4) ◽  
pp. 276-283 ◽  
Author(s):  
Yuping Cao ◽  
Wen Li ◽  
Jingjin Shen ◽  
Robert T. Malison ◽  
Yalin Zhang ◽  
...  

2020 ◽  
pp. 070674372097482
Author(s):  
Shane J. McInerney ◽  
Trisha Chakrabarty ◽  
Malgorzata Maciukiewicz ◽  
Benicio N. Frey ◽  
Glenda M. MacQueen ◽  
...  

Objectives: Major depressive disorder (MDD) is associated with impairments in both cognition and functioning. However, whether cognitive deficits significantly contribute to impaired psychosocial and occupational functioning, independent of other depressive symptoms, is not well established. We examined the relationship between cognitive performance and functioning in depressed patients before and after antidepressant treatment using secondary data from the first Canadian Biomarker Integration Network in Depression-1 study. Methods: Cognition was assessed at baseline in unmedicated, depressed participants with MDD ( n = 207) using the Central Nervous System Vital Signs computerized battery, psychosocial functioning with the Sheehan Disability Scale (SDS), and occupational functioning with the Lam Employment Absence and Productivity Scale (LEAPS). Cognition ( n = 181), SDS ( n = 175), and LEAPS ( n = 118) were reassessed after participants received 8 weeks of open-label escitalopram monotherapy. A series of linear regressions were conducted to determine (1) whether cognitive functioning was associated with psychosocial and occupational functioning prior to treatment, after adjusting for overall depressive symptom severity and (2) whether changes in cognitive functioning after an 8-week treatment phase were associated with changes in psychosocial and occupational functioning, after adjusting for changes in overall symptom severity. Results: Baseline global cognitive functioning, after adjusting for depression symptom severity and demographic variables, was associated with the SDS work/study subscale (β = −0.17; P = 0.03) and LEAPS productivity subscale (β = −0.17; P = 0.05), but not SDS total (β = 0.19; P = 0.12) or LEAPS total (β = 0.41; P = 0.17) scores. Although LEAPS and SDS scores showed significant improvements after 8 weeks of treatment ( P < 0.001), there were no significant associations between changes in cognitive domain scores and functional improvements. Conclusion: Cognition was associated with occupational functioning at baseline, but changes in cognition were not associated with psychosocial or occupational functional improvements following escitalopram treatment. We recommend the use of more comprehensive functional assessments to determine the impact of cognitive change on functional outcomes in future research.


2021 ◽  
Author(s):  
Emma Morton ◽  
Venkat Bhat ◽  
Peter Giacobbe ◽  
Wendy Lou ◽  
Erin E. Michalak ◽  
...  

Abstract Introduction Many individuals with major depressive disorder (MDD) do not respond to initial antidepressant monotherapy. Adjunctive aripiprazole is recommended for treatment non-response; however, the impacts on quality of life (QoL) for individuals who receive this second-line treatment strategy have not been described. Methods We evaluated secondary QoL outcomes in patients with MDD (n=179). After 8 weeks of escitalopram, non-responders (<50% decrease in clinician-rated depression) were treated with adjunctive aripiprazole for 8 weeks (n=97); responders continued escitalopram (n=82). A repeated-measures ANOVA evaluated change in Quality of Life Enjoyment and Satisfaction Short Form scores. QoL was described relative to normative benchmarks. Results Escitalopram responders experienced the most QoL improvements in the first treatment phase. For non-responders, QoL improved with a large effect during adjunctive aripiprazole treatment. At the endpoint, 47% of patients achieving symptomatic remission still had impaired QoL. Discussion Individuals who were treated with adjunctive aripiprazole after non-response to escitalopram experienced improved QoL, but a substantial degree of QoL impairment persisted. Since QoL deficits may predict MDD recurrence, attention to ways to support this outcome is required.


2013 ◽  
Vol 30 (7) ◽  
pp. 697-712 ◽  
Author(s):  
Claudio Mencacci ◽  
Eugenio Aguglia ◽  
Giovanni Biggio ◽  
Lodovico Cappellari ◽  
Guido Di Sciascio ◽  
...  

2016 ◽  
Vol 12 (3) ◽  
pp. 719-736
Author(s):  
Alexander Joseph Steiner ◽  
Stephanie Marie Wright ◽  
Taylor Kuhn ◽  
Waguih William IsHak

Sign in / Sign up

Export Citation Format

Share Document